{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:51:02Z","timestamp":1790743862473,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Princess Beatrix Fund"},{"DOI":"10.13039\/100018208","name":"Cure JM Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018208","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>JDM is a rare chronic immune-mediated inflammatory disease with a predominant role for type I IFN responses. We aimed to determine the potential of Siglec-1 expression on monocytes as a novel IFN-inducible biomarker for disease activity monitoring and prediction of treatment response in patients with JDM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Siglec-1 was measured by flow cytometry on circulating monocytes of 21 newly diagnosed JDM patients before start of treatment and, for 10 of these, also during follow-up. The expression levels of five type I IFN-stimulated genes, MX1, IFI44, IFI44L, LY6E and IFIT3, were measured by RT-qPCR to determine the IFN signature and calculate an IFN score. IFN-inducible plasma proteins CXCL10 and galectin-9 were measured by multiplex immunoassay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Siglec-1 and IFN score were increased in JDM patients compared with controls and correlated with clinical disease activity. Stratification of patients by Siglec-1 expression at diagnosis identified those with high Siglec-1 expression as having a higher risk of requiring treatment intensification within the first 3\u2009months after diagnosis (55% vs 0% of patients, P\u2009=\u20090.01). Siglec-1 expression strongly correlated with plasma levels of previously validated biomarkers CXCL10 (rs\u2009=\u20090.81, P\u2009&amp;lt;\u20090.0001) and galectin-9 (rs\u2009=\u20090.83, P\u2009&amp;lt;\u20090.0001), and was superior to the IFN score in predicting treatment response (area under the curve 0.87 vs 0.53, P\u2009=\u20090.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Siglec-1 on monocytes is a novel IFN-inducible biomarker in JDM that correlates with clinical disease activity and identifies patients at risk for a suboptimal treatment response. Further studies are required to validate these findings and their clinical potential.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keab601","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T19:12:09Z","timestamp":1628709129000},"page":"2144-2155","source":"Crossref","is-referenced-by-count":58,"title":["Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response"],"prefix":"10.1093","volume":"61","author":[{"given":"Butsabong","family":"Lerkvaleekul","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"},{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1626-353X","authenticated-orcid":false,"given":"Saskia R","family":"Veldkamp","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Marlot","family":"van der Wal","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J H","family":"Schatorj\u00e9","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Paediatric Rheumatology, Amalia Children's Hospital, Radboud University Medical Centre Nijmegen, Nijmegen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-352X","authenticated-orcid":false,"given":"Sylvia S M","family":"Kamphuis","sequence":"additional","affiliation":[{"name":"Paediatric Rheumatology, Sophia Children's Hospital, Erasmus University Medical Centre, Rotterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Merlijn","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Department of Pediatric Immunology, Rheumatology and Infectious Diseases, Emma Children's Hospital, Amsterdam University Medical Centers, Amsterdam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra C E","family":"Hissink Muller","sequence":"additional","affiliation":[{"name":"Department of Paediatric Rheumatology, Leiden University Medical Centre, Leiden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wineke","family":"Armbrust","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology and Immunology, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J","family":"Vastert","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Wienke","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H A","family":"Jansen","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annet","family":"van Royen-Kerkhof","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology and Immunology, Wilhelmina Children\u2019s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke","family":"van Wijk","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology, University Medical Center Utrecht, Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"2022050522162339500_keab601-B1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MD.0b013e31827f264d","article-title":"The clinical phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"Shah","year":"2013","journal-title":"Medicine"},{"key":"2022050522162339500_keab601-B2","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.3389\/fimmu.2018.02951","article-title":"Systemic and tissue inflammation in Juvenile dermatomyositis: from pathogenesis to the quest for monitoring tools","volume":"9","author":"Wienke","year":"2018","journal-title":"Front Immunol"},{"key":"2022050522162339500_keab601-B3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cyto.2014.11.026","article-title":"The role of type I interferons and other cytokines in dermatomyositis","volume":"73","author":"Arshanapalli","year":"2015","journal-title":"Cytokine"},{"key":"2022050522162339500_keab601-B4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.gene.2015.09.058","article-title":"The type I interferons: basic concepts and clinical relevance in immune-mediated inflammatory diseases","volume":"576","author":"Lopez de Padilla","year":"2016","journal-title":"Gene"},{"key":"2022050522162339500_keab601-B5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12016-020-08798-2","article-title":"Type I interferons in the pathogenesis and treatment of autoimmune diseases","volume":"59","author":"Jiang","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"2022050522162339500_keab601-B6","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022050522162339500_keab601-B7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1136\/annrheumdis-2012-201586","article-title":"IFNalpha and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus","volume":"72","author":"Rose","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022050522162339500_keab601-B8","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1002\/art.24936","article-title":"Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis","volume":"60","author":"Bilgic","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2022050522162339500_keab601-B9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg","year":"2012","journal-title":"Genes Immun"},{"key":"2022050522162339500_keab601-B10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clim.2006.05.011","article-title":"MxA gene expression in juvenile dermatomyositis peripheral blood mononuclear cells: association with muscle involvement","volume":"120","author":"O'Connor","year":"2006","journal-title":"Clin Immunol"},{"key":"2022050522162339500_keab601-B11","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022050522162339500_keab601-B12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.40800","article-title":"Muscle expression of type I and type II interferons is increased in juvenile dermatomyositis and related to clinical and histologic features","volume":"71","author":"Moneta","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022050522162339500_keab601-B13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-020-02160-9","article-title":"Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies","volume":"22","author":"Kim","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2022050522162339500_keab601-B14","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2022050522162339500_keab601-B15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2022050522162339500_keab601-B16","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1023\/A:1018588526788","article-title":"The potential role of sialoadhesin as a macrophage recognition molecule in health and disease","volume":"14","author":"Crocker","year":"1997","journal-title":"Glycoconj J"},{"key":"2022050522162339500_keab601-B17","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.4049\/jimmunol.166.6.3637","article-title":"Cutting edge: CD43 functions as a T cell counterreceptor for the macrophage adhesion receptor sialoadhesin (Siglec-1)","volume":"166","author":"van den Berg","year":"2001","journal-title":"J Immunol"},{"key":"2022050522162339500_keab601-B18","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/art.23404","article-title":"Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus","volume":"58","author":"Biesen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2022050522162339500_keab601-B19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/rheumatology\/ket342","article-title":"Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis","volume":"53","author":"Xiong","year":"2014","journal-title":"Rheumatology"},{"key":"2022050522162339500_keab601-B20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/1352458512458718","article-title":"SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis","volume":"19","author":"Malhotra","year":"2013","journal-title":"Mult Scler"},{"key":"2022050522162339500_keab601-B21","doi-asserted-by":"crossref","first-page":"e000292","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjogren's syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"key":"2022050522162339500_keab601-B22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2022050522162339500_keab601-B23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"key":"2022050522162339500_keab601-B24","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/rheumatology\/kel025","article-title":"Network for Juvenile Dermatomyositis PRES. An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM)","volume":"45","author":"Brown","year":"2006","journal-title":"Rheumatology"},{"key":"2022050522162339500_keab601-B25","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022050522162339500_keab601-B26","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022050522162339500_keab601-B27","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/art.39200","article-title":"Analysis of published criteria for clinically inactive disease in a large juvenile dermatomyositis cohort shows that skin disease is underestimated","volume":"67","author":"Almeida","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2022050522162339500_keab601-B28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Enders","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022050522162339500_keab601-B29","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/acr.22041","article-title":"Lack of achievement of a full score on the childhood myositis assessment scale by healthy four-year-olds and those recovering from juvenile dermatomyositis","volume":"65","author":"Quinones","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2022050522162339500_keab601-B30","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1002\/art.1780401109","article-title":"Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: i. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group","volume":"40","author":"Rider","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2022050522162339500_keab601-B31","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/rheumatology\/kem179","article-title":"The cutaneous assessment tool: development and reliability in juvenile idiopathic inflammatory myopathy","volume":"46","author":"Huber","year":"2007","journal-title":"Rheumatology"},{"key":"2022050522162339500_keab601-B32","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jim.2005.03.009","article-title":"Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies","volume":"300","author":"de Jager","year":"2005","journal-title":"J Immunol Methods"},{"key":"2022050522162339500_keab601-B33","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"2022050522162339500_keab601-B34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/annrheumdis-2012-201381","article-title":"Prevalence of interferon type I signature in CD14 monocytes of patients with Sj\u00f6gren\u2019s syndrome and association with disease activity and BAFF gene expression","volume":"72","author":"Brkic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022050522162339500_keab601-B35","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"2022050522162339500_keab601-B36","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/art.40881","article-title":"Galectin-9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis: a longitudinal cohort study and multicohort validation","volume":"71","author":"Wienke","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022050522162339500_keab601-B37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13075-018-1649-1","article-title":"The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus","volume":"20","author":"Oliveira","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2022050522162339500_keab601-B38","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/art.22382","article-title":"A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists","volume":"56","author":"York","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022050522162339500_keab601-B39","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/imm.12042","article-title":"Sialoadhesin - a macrophage-restricted marker of immunoregulation and inflammation","volume":"138","author":"O'Neill","year":"2013","journal-title":"Immunology"},{"key":"2022050522162339500_keab601-B40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1182\/blood.V97.1.288","article-title":"Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations","volume":"97","author":"Hartnell","year":"2001","journal-title":"Blood"},{"key":"2022050522162339500_keab601-B41","doi-asserted-by":"crossref","first-page":"e1967","DOI":"10.1371\/journal.pone.0001967","article-title":"Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity","volume":"3","author":"Rempel","year":"2008","journal-title":"PLoS One"},{"key":"2022050522162339500_keab601-B42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1046\/j.1365-2249.2000.01194.x","article-title":"Immunohistochemical study of lymphoid tissues in adjuvant arthritis (AA) by image analysis; relationship with synovial lesions","volume":"120","author":"Carol","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"2022050522162339500_keab601-B43","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain"},{"key":"2022050522162339500_keab601-B44","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1093\/rheumatology\/keaa657","article-title":"Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?","volume":"60","author":"Heinen","year":"2021","journal-title":"Rheumatology"},{"key":"2022050522162339500_keab601-B45","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/art.41236","article-title":"Endothelial and inflammation biomarker profiles at diagnosis reflecting clinical heterogeneity and serving as a prognostic tool for treatment response in two independent cohorts of patients with juvenile dermatomyositis","volume":"72","author":"Wienke","year":"2020","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab601\/40452620\/keab601.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/2144\/43562203\/keab601.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/5\/2144\/43562203\/keab601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T07:17:18Z","timestamp":1699341438000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/5\/2144\/6350498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,8,13]]},"published-print":{"date-parts":[[2022,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab601","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,8,13]]}}}